方盛制药拟受让“复方醋酸地塞米松乳膏”药品上市许可

Core Viewpoint - Fangsheng Pharmaceutical (603998.SH) has signed a technology transfer contract with Yifan Pharmaceutical to acquire the marketing authorization for "Compound Dexamethasone Acetate Cream," which includes ownership of the drug prescription, production process, technical secrets, related patents, and technical data [1] Group 1: Strategic Development - The company aims to become a health industry group centered on innovative traditional Chinese medicine, continuously increasing R&D investment while also acquiring products with development potential to enrich its product pipeline [1] - The acquisition of the marketing authorization is aligned with the company's development strategy, facilitating industry chain integration and expansion, thereby enhancing market competitiveness [1] Group 2: Product Expansion - Following the acquisition, the company's dermatological product category will be effectively expanded, with the potential for new profit growth through brand empowerment within the group [1]